Search results

Skip to results

Type

Status

Last updated

Showing 1 to 6 of 6 results for daclatasvir

  1. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA499

  2. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

    Technology appraisal guidance
    Published
    25 November 2015

  3. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430

  4. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA365

  5. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA363

  6. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA413